Bioceltix begins the next phase of research

We made the next important step on the way to the registration of our drug candidates in the European Medicines Agency. The next phase of ...

Read full

Increasing the company’s share capital

In connection with the issue of series G shares, on April 23, 2021, an increase in the share capital was registered. All formalities related to ...

Read full

Investor relations

At Bioceltix, we develop innovative MSC-based biopharmaceuticals for use in companion animals. We target markets with high demand for effective pharmaceuticals.

More »

Wrote about us

Puls Biznesu about our plans: Bioceltix announces that it will soon debut on NewConnect – the company has recently completed the pre-IPO round. So far, the company has obtained a total of approx. PLN 20 million in financing for the development of a still innovative method of treating pets using drugs with stem cells.


More »